It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia.
The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Question: What is ambroxol and what is the rationale for its use in the treatment of Parkinson’s Disease dementia? (0:14)
Disclosures: Stephen Pasternak has received consulting fees from Zywie Bio LLC.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
